Want to see LBRX full AI Analyst Report?
LBRX Stock Chart & Stats
$30.52
--
Market closed
$30.52
--
Day’s Range― - ―
52-Week Range$13.36 - $41.33
Previous CloseN/A
VolumeN/A
Average Volume (3M)239.05K
Market Cap
$1.15B
Enterprise Value$544.53M
Total Cash (Recent Filing)$365.64M
Total Debt (Recent Filing)$3.47M
Price to Earnings (P/E)―
Beta1.29
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding28,676,653
10 Day Avg. Volume318,803
30 Day Avg. Volume239,047
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)1.87
Price to Sales (P/S)0.00
P/FCF Ratio-15.97
Enterprise Value/Market Cap0.47
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.64K
Enterprise Value/Ebitda-13.94
Forecast
1Y Price Target
$47.43Price Target Upside55.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA markedly stronger balance sheet with roughly $301M equity and minimal debt materially improves solvency and financing optionality. This durable capital base lengthens runway, reduces immediate dilution pressure and gives management flexibility to fund pivotal trials and regulatory activities over the next 2–3 years.
Recent $150M FinancingA committed $150M private placement is a structural capital event that materially extends development funding. It supports multiple late‑stage readouts and broader indication studies, lowers near-term financing risk, and enables execution of the clinical plan without immediate reliance on dilutive bridge financings.
Accelerated Phase 3 TimelineFaster enrollment and an earlier topline readout compress the time to pivotal data and potential regulatory engagement. This shortens the commercialization horizon, reduces exposure to long enrollment risks, and allows earlier strategic decisions on partnerships, label planning and additional indications if data are positive.
Bears Say
No Revenue / Ongoing LossesAs a development-stage biotech the company has no product revenue and sustained net losses; this structural lack of operating income means the business cannot self-fund and remains fully dependent on capital markets and milestone/licensing outcomes to reach commercialization and achieve profitability.
Persistent Negative Cash FlowConsistently negative operating and free cash flow reflects ongoing burn to fund trials. Even with recent financing, structural negative cash generation raises the probability of future raises over the medium term, which can dilute existing equity and constrain long‑term planning absent successful product milestones.
Concentrated Single‑asset PipelineThe company’s strategy is heavily concentrated on LB-102 and CNS indications, creating binary program risk. A failed or delayed pivotal readout would materially impair commercial prospects and leave limited near-term alternatives for revenue or offsetting value, raising long‑term execution risk.
LB Pharmaceuticals, Inc. News
LBRX FAQ
What was LB Pharmaceuticals, Inc.’s price range in the past 12 months?
LB Pharmaceuticals, Inc. lowest stock price was $13.36 and its highest was $41.33 in the past 12 months.
What is LB Pharmaceuticals, Inc.’s market cap?
LB Pharmaceuticals, Inc.’s market cap is $1.15B.
When is LB Pharmaceuticals, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were LB Pharmaceuticals, Inc.’s earnings last quarter?
Currently, no data Available
Is LB Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts LB Pharmaceuticals, Inc.’s price is currently Undervalued.
Does LB Pharmaceuticals, Inc. pay dividends?
LB Pharmaceuticals, Inc. does not currently pay dividends.
What is LB Pharmaceuticals, Inc.’s EPS estimate?
LB Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LB Pharmaceuticals, Inc. have?
LB Pharmaceuticals, Inc. has 28,676,653 shares outstanding.
What happened to LB Pharmaceuticals, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of LB Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in LBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LB Pharmaceuticals, Inc. Stock Smart Score
Company Description
LB Pharmaceuticals, Inc.
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
LBRX Stock 12 Month Forecast
Average Price Target
$47.43
▲(55.40% Upside)
Technical Analysis
Ownership Overview
24.62% Insiders
13.45% Mutual Funds
0.46% Other Institutional Investors
52.55% Public Companies and
Individual Investors